Biotech Analyst Minter, along with expert Dr. David Lynch, discuss current treatment options and potential therapeutic modalities for patients living with Friedreich’s ataxia (FA), preview Larimar’s Phase II top-line data readout for 50mg dose of nomlabofusp (CTI-1601) and provide an update on Biogen’s Skyclarys on an Analyst/Industry conference call to be held on January 31 at 3 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BIIB:
